stoxline Quote Chart Rank Option Currency Glossary
  
Marker Therapeutics, Inc. (MRKR)
4.14  -0.15 (-3.5%)    11-08 16:00
Open: 4.3525
High: 4.39
Volume: 12,593
  
Pre. Close: 4.29
Low: 4
Market Cap: 37(M)
Technical analysis
2024-11-08 4:47:54 PM
Short term     
Mid term     
Targets 6-month :  5.86 1-year :  6.84
Resists First :  5.01 Second :  5.86
Pivot price 4.04
Supports First :  3.42 Second :  2.44
MAs MA(5) :  3.88 MA(20) :  3.88
MA(100) :  3.87 MA(250) :  4.01
MACD MACD :  0.2 Signal :  0.2
%K %D K(14,3) :  45.6 D(3) :  38.3
RSI RSI(14): 58.1
52-week High :  6.15 Low :  2.44
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ MRKR ] has closed below upper band by 42.4%. Bollinger Bands are 13.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.39 - 4.41 4.41 - 4.43
Low: 3.95 - 3.97 3.97 - 3.99
Close: 4.1 - 4.14 4.14 - 4.17
Company Description

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

Headline News

Wed, 23 Oct 2024
US Penny Stocks To Consider In October 2024 - Simply Wall St

Wed, 14 Aug 2024
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire

Mon, 12 Aug 2024
Marker Therapeutics Awarded $2 Million Grant from NIH in - GlobeNewswire

Fri, 29 Mar 2024
symbol__ Stock Quote Price and Forecast - CNN

Mon, 08 Jan 2024
Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization - Yahoo Finance

Mon, 01 May 2023
7 Low Float Penny Stocks To Watch After SNTG Stock Explodes - Penny Stocks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 9 (M)
Shares Float 7 (M)
Held by Insiders 12.1 (%)
Held by Institutions 22.6 (%)
Shares Short 61 (K)
Shares Short P.Month 65 (K)
Stock Financials
EPS -1.15
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.09
Profit Margin -278.3 %
Operating Margin -197.4 %
Return on Assets (ttm) -40.9 %
Return on Equity (ttm) -71.8 %
Qtrly Rev. Growth 53.2 %
Gross Profit (p.s.) 0
Sales Per Share 0.41
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -11 (M)
Levered Free Cash Flow -7 (M)
Stock Valuations
PE Ratio -3.6
PEG Ratio 0
Price to Book value 3.79
Price to Sales 9.9
Price to Cash Flow -3.39
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android